Rezolute, Inc. — Form 10-Q Summary
Period note: The filing covers the three months ended September 30, 2020, Rezolute’s first quarter of fiscal 2021—not calendar 2020 Q1. Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise noted.
Business context and reporting period
Rezolute is a clinical-stage biopharmaceutical company with no commercial products and no revenue to date. Its lead candidate, RZ358, was in Phase 2b development for congenital hyperinsulinism (CHI); RZ402 is an oral candidate for diabetic macular edema (DME). The interim financial statements are unaudited.
Financial performance, cash flow and liquidity
| Metric | Quarter ended Sep. 30, 2020 | Comparable 2019 quarter |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.344 | $3.234 |
| General and administrative expense | $1.279 | $1.945 |
| Total operating expense / operating loss | $3.623 | $5.179 |
| Net loss | $3.620 | $5.080 |
| Net loss per share, basic and diluted | $0.62 | $0.94 |
| Net cash used in operating activities | $3.551 | $8.929 |
| Cash and cash equivalents at quarter-end | $6.404 | $22.104 cash and $3.111 restricted cash |
At September 30, 2020, total assets were $7.410, total liabilities $3.028, and stockholders’ equity $4.382. Working capital was approximately $4.0 million. Liabilities included $1.409 million payable to Xoma and $0.349 million in operating lease liabilities. The filing reports no revenue or gross profit, so operating margins are not meaningful. No interest-bearing borrowings are identified in the presented balance sheet.
After quarter-end, Rezolute completed a private placement on October 9, 2020, raising $41.0 million gross and approximately $37.5 million net. The financing comprised approximately 2.5 million common shares and warrants for approximately 0.8 million shares, exercisable at $19.50 for seven years. The company paid Xoma $1.4 million on October 23 after the financing accelerated the remaining license payment. Management said cash on hand plus financing proceeds should fund planned activities until the second half of fiscal 2022.
Material changes versus the prior comparable period
- Net loss narrowed by $1.460 million, or approximately 29%; total operating expenses fell 30% to $3.623 million.
- R&D expense declined 28%, with lower clinical trial, consulting, personnel and facilities spending. Management attributed reduced activity in part to COVID-19 disruptions and noted that the prior-year quarter included AB101 costs; the company discontinued further development of AB101.
- G&A expense fell 34%, chiefly because of lower stock-based compensation and cash compensation.
- Operating cash use decreased by $5.378 million. The comparison was also affected by operating liability movements, particularly Xoma payments: the 2019 quarter included a $4.891 million reduction in Xoma payables.
- Unlike the 2019 quarter, which included $22.571 million net cash from financing, the 2020 quarter had no financing cash inflow. Cash declined $3.551 million during the quarter.
Outlook, risks and unusual items
- RZ358: The global Phase 2b RIZE trial was paused in March 2020 because of COVID-19. The company said trial activities were resuming, expected enrollment to recommence by year-end 2020, and projected study completion in the second half of calendar 2021 if enrollment resumed on that timetable. U.S. enrollment was anticipated in the first quarter of calendar 2021. FDA granted RZ358 Rare Pediatric Disease designation, which could qualify it for a priority review voucher upon marketing approval.
- RZ402: Rezolute submitted an IND to the FDA on October 28, 2020. Acceptance would trigger a $1.0 million ActiveSite milestone payment; management anticipated a Phase 1 trial before the end of the first quarter of calendar 2021, assuming timely FDA acceptance.
- COVID-19: Management said the period’s financial results were not significantly affected, but trial enrollment, site initiation, trial duration and costs remain uncertain. The company warned that disruption to employees, suppliers, manufacturing or financing access could adversely affect results and liquidity.
- Funding and obligations: Rezolute expects ongoing operating losses and will need additional capital after its estimated runway; future financing may be unavailable or unacceptable on desired terms. Xoma license terms include up to $37.0 million in clinical and regulatory milestones, plus potential sales-based royalties and up to $185.0 million in additional sales milestones. ActiveSite terms include up to $46.5 million in milestones and 2% royalties.
- Other subsequent events: The company effected a 1-for-50 reverse stock split on October 9, 2020 and received Nasdaq Capital Market listing approval on November 3. It approved approximately $0.4 million in employee and officer bonuses, to be expensed in the December 2020 quarter. A new Oregon office lease was entered into in October; its right-of-use asset and lease liability had not yet been determined.
- Controls and contingencies: Management reported a material weakness in internal control over financial reporting due to inadequate segregation of duties arising from limited staffing; remediation was incomplete. The filing reports no pending or threatened litigation expected to have a material effect. Registration failure under the financing agreement could result in liquidated damages of up to 6% of gross proceeds.
Important facts for investors to verify
- Whether RIZE enrollment resumed on the stated schedule and how COVID-19 affects trial timing, costs and data.
- Actual remaining cash runway after financing costs, Xoma repayment, bonuses, and planned RZ358/RZ402 spending; the stated runway is management’s estimate.
- FDA acceptance of the RZ402 IND, timing of Phase 1 initiation, and the resulting $1.0 million milestone obligation.
- Progress in remediating the disclosed material weakness in internal controls.
- Final registration of the financing shares and warrants, and any potential registration-related damages or dilution from warrants and other equity awards.
- The filing’s stated quarter-end share count reflects the reverse split; confirm post-financing shares and subsequent capitalization in later filings.